{"hands_on_practices": [{"introduction": "In managing advanced thyroid cancer, understanding the pace of disease progression is as important as knowing its extent. Thyroglobulin doubling time (Tg-DT) provides a dynamic measure of tumor growth kinetics, serving as a powerful prognostic marker that can predict outcomes and guide the timing of therapeutic interventions. This exercise [@problem_id:4790966] will walk you through deriving and calculating Tg-DT from first principles of exponential growth, a fundamental quantitative skill for risk-stratifying patients with biochemically progressive disease.", "problem": "A patient with radioactive iodine-refractory differentiated thyroid carcinoma is on a vascular endothelial growth factor receptor tyrosine kinase inhibitor (TKI). Under consistent thyroid-stimulating hormone (TSH) suppression and the same thyroglobulin (Tg) assay with stable anti-thyroglobulin antibody status, serial serum thyroglobulin (Tg) concentrations were obtained at two time points separated by a known interval. The first measurement was $Tg_1 = 10$ ng/mL and the second was $Tg_2 = 20$ ng/mL, with an interval $\\Delta t = 12$ months between measurements. Assume that, over this interval, Tg follows exponential kinetics driven by net tumor cell population dynamics, and that Tg is a proportional biomarker of tumor burden.\n\nUsing only core principles of exponential growth and the definition of doubling time, first derive from first principles a general expression for the Tg doubling time $DT$ in terms of $Tg_1$, $Tg_2$, and $\\Delta t$. Then compute the numerical value of $DT$ for the given data, expressing $DT$ in months. Finally, encode a binary risk indicator $R$ for near-term radiographic progression, defined as $R = 1$ if $DT < 6$ months and $R = 0$ otherwise, based on the well-established observation that shorter biomarker doubling times reflect more aggressive disease kinetics in advanced thyroid cancer. Provide the exact values; do not round. Report your final answer as a row matrix $\\begin{pmatrix} DT & R \\end{pmatrix}$, where $DT$ is in months and $R$ is unitless.", "solution": "The problem as stated is valid. It is scientifically grounded in the principles of clinical oncology and mathematical modeling, well-posed with sufficient and consistent data, and objective in its formulation. We can therefore proceed to a solution.\n\nThe problem requires the derivation of the thyroglobulin doubling time ($DT$) from first principles, followed by a calculation of its value and a corresponding risk indicator. The fundamental assumption is that the serum thyroglobulin concentration, $Tg(t)$, follows an exponential growth model over the observation interval. This model is expressed by the differential equation $\\frac{d(Tg)}{dt} = k \\cdot Tg$, where $k$ is the constant relative growth rate.\n\nThe solution to this first-order linear ordinary differential equation is:\n$$Tg(t) = Tg_0 \\exp(kt)$$\nwhere $Tg_0$ is the thyroglobulin concentration at an initial time $t=0$.\n\nLet the first measurement, $Tg_1$, be taken at time $t_1$, and the second measurement, $Tg_2$, be taken at time $t_2$. The time interval between these measurements is $\\Delta t = t_2 - t_1$. According to the model, we can write:\n$$Tg_1 = Tg(t_1) = Tg_0 \\exp(kt_1)$$\n$$Tg_2 = Tg(t_2) = Tg_0 \\exp(kt_2)$$\n\nTo find the growth rate constant $k$ in terms of the given measurements, we take the ratio of $Tg_2$ to $Tg_1$:\n$$\\frac{Tg_2}{Tg_1} = \\frac{Tg_0 \\exp(kt_2)}{Tg_0 \\exp(kt_1)} = \\exp(k(t_2 - t_1)) = \\exp(k \\Delta t)$$\n\nTo solve for $k$, we take the natural logarithm of both sides of the equation:\n$$\\ln\\left(\\frac{Tg_2}{Tg_1}\\right) = \\ln(\\exp(k \\Delta t))$$\n$$\\ln(Tg_2) - \\ln(Tg_1) = k \\Delta t$$\n$$k = \\frac{\\ln(Tg_2) - \\ln(Tg_1)}{\\Delta t}$$\n\nNext, we derive the expression for the doubling time, $DT$. The doubling time is defined as the time interval over which the quantity of interest doubles. Let us consider an arbitrary time $t$ with concentration $Tg(t)$. We seek the time interval $DT$ such that at time $t+DT$, the concentration is $2 \\cdot Tg(t)$.\n$$Tg(t+DT) = 2 \\cdot Tg(t)$$\nSubstituting the exponential growth formula:\n$$Tg_0 \\exp(k(t+DT)) = 2 \\cdot Tg_0 \\exp(kt)$$\nDividing both sides by $Tg_0 \\exp(kt)$ (which is non-zero) yields:\n$$\\exp(kDT) = 2$$\nTaking the natural logarithm of both sides gives:\n$$k \\cdot DT = \\ln(2)$$\nThus, the doubling time is:\n$$DT = \\frac{\\ln(2)}{k}$$\n\nNow, we substitute the expression for $k$ we derived earlier into this equation to obtain a general formula for $DT$ in terms of $Tg_1$, $Tg_2$, and $\\Delta t$:\n$$DT = \\frac{\\ln(2)}{\\frac{\\ln(Tg_2) - \\ln(Tg_1)}{\\Delta t}}$$\n$$DT = \\frac{\\Delta t \\cdot \\ln(2)}{\\ln(Tg_2) - \\ln(Tg_1)} = \\frac{\\Delta t \\cdot \\ln(2)}{\\ln\\left(\\frac{Tg_2}{Tg_1}\\right)}$$\nThis is the required general expression for the doubling time derived from first principles.\n\nWe are given the following specific values:\n- First measurement, $Tg_1 = 10 \\text{ ng/mL}$.\n- Second measurement, $Tg_2 = 20 \\text{ ng/mL}$.\n- Time interval, $\\Delta t = 12 \\text{ months}$.\n\nSubstituting these values into the derived formula for $DT$:\n$$DT = \\frac{12 \\cdot \\ln(2)}{\\ln\\left(\\frac{20}{10}\\right)} = \\frac{12 \\cdot \\ln(2)}{\\ln(2)}$$\n$$DT = 12 \\text{ months}$$\n\nThe problem also defines a binary risk indicator, $R$, for near-term radiographic progression. The rule is:\n$$R = 1 \\text{ if } DT < 6 \\text{ months}$$\n$$R = 0 \\text{ if } DT \\geq 6 \\text{ months}$$\n\nUsing our calculated value of $DT = 12$ months, we evaluate the condition:\nIs $12 < 6$? The condition is false.\nTherefore, the risk indicator $R$ is $0$.\n\nThe final answer is to be reported as a row matrix $\\begin{pmatrix} DT & R \\end{pmatrix}$.\nSubstituting our results, we have $\\begin{pmatrix} 12 & 0 \\end{pmatrix}$.", "answer": "$$\\boxed{\\begin{pmatrix} 12 & 0 \\end{pmatrix}}$$", "id": "4790966"}, {"introduction": "Once a patient with advanced thyroid cancer begins systemic therapy, clinicians require a standardized, objective method to determine if the treatment is effective. The Response Evaluation Criteria in Solid Tumors (RECIST) provides this essential framework, allowing for consistent assessment of changes in tumor burden across different clinical trials and practice settings. This practical problem [@problem_id:4790890] simulates the real-world task of applying RECIST 1.1 criteria to serial imaging results, a critical skill for making evidence-based decisions about continuing, modifying, or stopping a given therapy.", "problem": "A $58$-year-old person with radioactive iodineâ€“refractory differentiated thyroid carcinoma begins systemic therapy with a multikinase inhibitor. Computed tomography with slice thickness $\\leq 5$ $\\mathrm{mm}$ identifies measurable target lesions per the Response Evaluation Criteria in Solid Tumors (RECIST) version $1.1$ at baseline. Under RECIST $1.1$, measurable non-nodal target lesions are measured by the longest diameter and measurable lymph node target lesions are measured by the short axis; up to $5$ target lesions total with no more than $2$ per organ are selected. For lymph nodes, a short axis of $\\geq 15$ $\\mathrm{mm}$ at baseline qualifies for target selection; lymph nodes with short axis $< 10$ $\\mathrm{mm}$ at follow-up are considered normal and recorded as $0$ in the sum. Partial response requires a decrease of at least $30\\%$ in the sum of target lesion measurements from baseline, progressive disease requires an increase of at least $20\\%$ in the sum from the smallest prior sum (nadir) with an absolute increase of at least $5$ $\\mathrm{mm}$, and stable disease is defined as neither of these, assuming no new lesions and no unequivocal progression of non-target lesions.\n\nBaseline target lesions ($n = 5$) and their qualifying diameters are:\n- Right upper lobe pulmonary metastasis, longest diameter $24$ $\\mathrm{mm}$.\n- Left lower lobe pulmonary metastasis, longest diameter $18$ $\\mathrm{mm}$.\n- Retrotracheal lymph node, short axis $16$ $\\mathrm{mm}$.\n- Left level IV cervical lymph node, short axis $17$ $\\mathrm{mm}$.\n- Hepatic segment VII lesion, longest diameter $20$ $\\mathrm{mm}$.\n\nFirst follow-up at $12$ weeks shows:\n- Right upper lobe pulmonary metastasis, longest diameter $15$ $\\mathrm{mm}$.\n- Left lower lobe pulmonary metastasis, longest diameter $12$ $\\mathrm{mm}$.\n- Retrotracheal lymph node, short axis $9$ $\\mathrm{mm}$.\n- Left level IV cervical lymph node, short axis $11$ $\\mathrm{mm}$.\n- Hepatic segment VII lesion, longest diameter $14$ $\\mathrm{mm}$.\n\nSecond follow-up at $24$ weeks shows:\n- Right upper lobe pulmonary metastasis, longest diameter $22$ $\\mathrm{mm}$.\n- Left lower lobe pulmonary metastasis, longest diameter $17$ $\\mathrm{mm}$.\n- Retrotracheal lymph node, short axis $13$ $\\mathrm{mm}$.\n- Left level IV cervical lymph node, short axis $14$ $\\mathrm{mm}$.\n- Hepatic segment VII lesion, longest diameter $19$ $\\mathrm{mm}$.\n\nAssume there are no new lesions and no unequivocal progression among non-target lesions at either follow-up. Using the RECIST $1.1$ rules above, compute the decimal fraction representing the percentage change in the sum of target lesion measurements from the nadir to the $24$-week follow-up. Round your answer to four significant figures and express it as a unitless decimal fraction without a percentage sign.", "solution": "The problem is valid as it is scientifically grounded in the established RECIST $1.1$ criteria from clinical oncology, is well-posed with all necessary data, and is formulated objectively. The solution requires a systematic application of the provided rules.\n\nLet $S_0$ be the sum of the diameters of the target lesions at baseline. The given measurements are $24$ $\\mathrm{mm}$, $18$ $\\mathrm{mm}$, $16$ $\\mathrm{mm}$, $17$ $\\mathrm{mm}$, and $20$ $\\mathrm{mm}$.\n$$S_0 = 24 + 18 + 16 + 17 + 20 = 95 \\, \\mathrm{mm}$$\n\nLet $S_1$ be the sum of the diameters of the target lesions at the first follow-up at $12$ weeks. The measurements are $15$ $\\mathrm{mm}$, $12$ $\\mathrm{mm}$, $9$ $\\mathrm{mm}$, $11$ $\\mathrm{mm}$, and $14$ $\\mathrm{mm}$. According to the RECIST $1.1$ rules, a target lymph node with a short axis measurement of $< 10$ $\\mathrm{mm}$ is considered normal and its measurement is recorded as $0$ in the sum. The retrotracheal lymph node has a short axis of $9$ $\\mathrm{mm}$, which is less than $10$ $\\mathrm{mm}$. Therefore, its contribution to the sum is $0$ $\\mathrm{mm}$.\n$$S_1 = 15 + 12 + 0 + 11 + 14 = 52 \\, \\mathrm{mm}$$\n\nLet $S_2$ be the sum of the diameters of the target lesions at the second follow-up at $24$ weeks. The measurements are $22$ $\\mathrm{mm}$, $17$ $\\mathrm{mm}$, $13$ $\\mathrm{mm}$, $14$ $\\mathrm{mm}$, and $19$ $\\mathrm{mm}$. The retrotracheal lymph node measures $13$ $\\mathrm{mm}$, which is not less than $10$ $\\mathrm{mm}$, so the measured value is used.\n$$S_2 = 22 + 17 + 13 + 14 + 19 = 85 \\, \\mathrm{mm}$$\n\nThe nadir is defined as the smallest sum of diameters recorded from baseline up to the time point preceding the current evaluation. For the evaluation at $24$ weeks, the nadir is the minimum of the sums at baseline ($S_0$) and the first follow-up ($S_1$).\n$$S_{\\text{nadir}} = \\min(S_0, S_1) = \\min(95 \\, \\mathrm{mm}, 52 \\, \\mathrm{mm}) = 52 \\, \\mathrm{mm}$$\n\nThe problem requires the calculation of the decimal fraction representing the percentage change in the sum of measurements from the nadir to the $24$-week follow-up. Let this quantity be denoted by $F$.\n$$F = \\frac{S_2 - S_{\\text{nadir}}}{S_{\\text{nadir}}}$$\n\nSubstituting the calculated values into the formula:\n$$F = \\frac{85 - 52}{52} = \\frac{33}{52}$$\n\nTo express this as a decimal fraction, we perform the division:\n$$F = \\frac{33}{52} \\approx 0.63461538\\dots$$\n\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $6$, $3$, $4$, and $6$. The fifth significant figure is $1$, which is less than $5$, so we round down (i.e., we do not change the fourth figure).\n$$F \\approx 0.6346$$\n\nThis decimal fraction represents an increase of approximately $63.46\\%$ from the nadir sum.", "answer": "$$\\boxed{0.6346}$$", "id": "4790890"}, {"introduction": "The advent of tyrosine kinase inhibitors (TKIs) like lenvatinib has transformed the treatment landscape for radioactive iodine-refractory thyroid cancer, but their efficacy is coupled with a predictable spectrum of on-target toxicities. Proactive and guideline-based management of these adverse events is essential for maintaining patients on effective therapy, optimizing their quality of life, and ensuring safety. This clinical scenario [@problem_id:4790919] challenges you to apply evidence-based principles to manage common toxicities of lenvatinib, reinforcing the dose-modification and monitoring strategies that are vital in daily oncologic practice.", "problem": "A $62$-year-old man with radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC) is initiated on lenvatinib $24\\,\\mathrm{mg}$ orally once daily. Baseline blood pressure (BP) is $128/76\\,\\mathrm{mmHg}$ and urinalysis shows $0$ to $1+$ protein by dipstick. After $3$ weeks of therapy, his clinic BP is $168/102\\,\\mathrm{mmHg}$ on two measurements despite optimization to two antihypertensive agents, meeting Common Terminology Criteria for Adverse Events (CTCAE) grade $3$ hypertension. Urine dipstick is $0$ to $1+$ protein. You hold lenvatinib and intensify antihypertensive therapy. When BP control is achieved to grade $\\le 2$ (for example, systolic BP $<160\\,\\mathrm{mmHg}$ and diastolic BP $<100\\,\\mathrm{mmHg}$), lenvatinib is resumed. At week $7$, he develops new $3+$ protein on urine dipstick; a $24$-hour urine collection confirms protein excretion of $4.2\\,\\mathrm{g}/24\\,\\mathrm{h}$ without edema, consistent with CTCAE grade $3$ proteinuria. Lenvatinib is held again and supportive measures are provided. Proteinuria improves to $1.6\\,\\mathrm{g}/24\\,\\mathrm{h}$.\n\nUsing fundamental pharmacology and toxicity management principles for vascular endothelial growth factor (VEGF) pathway inhibitors, determine the appropriate stepwise lenvatinib dose reductions from $24\\,\\mathrm{mg}$ in response to grade $3$ hypertension and then grade $3$ proteinuria, and specify clinically appropriate monitoring intervals for blood pressure and urine protein that align with evidence-based guidance. Which of the following management plans is most appropriate?\n\nA. Withhold lenvatinib for grade $3$ hypertension; resume at $20\\,\\mathrm{mg}$ once BP is controlled to grade $\\le 2$. On subsequent grade $3$ proteinuria ($\\ge 3.5\\,\\mathrm{g}/24\\,\\mathrm{h}$), withhold and resume at $14\\,\\mathrm{mg}$ when proteinuria is $\\le 2.0\\,\\mathrm{g}/24\\,\\mathrm{h}$. Monitor BP at least weekly for the first $2$ months and then periodically; monitor urine protein at baseline and every $4$ weeks, obtaining a $24$-hour urine if dipstick is $\\ge 2+$. \n\nB. Continue lenvatinib at $24\\,\\mathrm{mg}$ during grade $3$ hypertension while adding antihypertensives; monitor BP monthly. For grade $3$ proteinuria, continue lenvatinib at $24\\,\\mathrm{mg}$ and monitor urine protein every $3$ months.\n\nC. For grade $3$ hypertension, reduce lenvatinib directly to $18\\,\\mathrm{mg}$ without interruption; for grade $3$ proteinuria, reduce further to $10\\,\\mathrm{mg}$. Monitor BP daily in clinic for $2$ weeks and urine protein weekly thereafter.\n\nD. Permanently discontinue lenvatinib for any grade $3$ toxicity; instruct the patient to measure BP three times daily at home and check urine protein only if edema develops.\n\nE. Withhold lenvatinib for grade $3$ hypertension; resume at $14\\,\\mathrm{mg}$ when BP is grade $\\le 2$. For grade $3$ proteinuria, withhold and resume at $20\\,\\mathrm{mg}$. Monitor BP twice weekly for $4$ weeks and urine protein every $2$ months.", "solution": "The problem statement is evaluated for validity prior to any attempt at a solution.\n\n**Step 1: Extract Givens**\n- **Patient Profile:** A $62$-year-old male.\n- **Diagnosis:** Radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC).\n- **Initial Treatment:** Lenvatinib $24\\,\\mathrm{mg}$ orally once daily.\n- **Baseline Data:**\n    - Blood Pressure (BP): $128/76\\,\\mathrm{mmHg}$.\n    - Urinalysis: $0$ to $1+$ protein by dipstick.\n- **Event at Week 3:**\n    - Toxicity: Grade $3$ hypertension, as per Common Terminology Criteria for Adverse Events (CTCAE), with BP of $168/102\\,\\mathrm{mmHg}$.\n    - Urinalysis: Unchanged at $0$ to $1+$ protein.\n    - Intervention: Lenvatinib was held and antihypertensive therapy was intensified.\n    - Condition for Resumption: BP control to Grade $\\le 2$ (systolic BP $<160\\,\\mathrm{mmHg}$ and diastolic BP $<100\\,\\mathrm{mmHg}$).\n- **Event at Week 7:**\n    - Toxicity: Grade $3$ proteinuria, with new $3+$ protein on dipstick, confirmed as $4.2\\,\\mathrm{g}/24\\,\\mathrm{h}$ by $24$-hour urine collection. No edema was present.\n    - Intervention: Lenvatinib was held again.\n    - Resolution: Proteinuria improved to $1.6\\,\\mathrm{g}/24\\,\\mathrm{h}$.\n- **Question:** Determine the correct stepwise dose reductions for lenvatinib and the appropriate monitoring intervals for BP and urine protein.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is scientifically sound. Lenvatinib is a vascular endothelial growth factor (VEGF) receptor inhibitor, and hypertension and proteinuria are well-documented, mechanistically plausible, on-target toxicities of this drug class. The presented clinical scenario, including the initial dose, development of Grade $3$ toxicities, and the values measured, are consistent with data from pivotal clinical trials (e.g., the SELECT trial) and the drug's established prescribing information. The use of CTCAE for grading toxicity is standard in oncology.\n- **Well-Posedness:** The problem is well-posed. It presents a clear sequence of clinical events and asks for the application of standard, guideline-directed management principles. The information provided is sufficient to determine a single correct course of action based on evidence-based medicine.\n- **Objectivity:** The problem is stated using objective, quantitative clinical data and standard medical terminology. It is free of ambiguity or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem is **valid**. It is a standard clinical case requiring knowledge of pharmacology and toxicity management. A solution will be derived based on the established prescribing information for lenvatinib.\n\n**Derivation of Solution**\nThe management of adverse reactions to lenvatinib is guided by its FDA-approved prescribing information, which outlines specific actions for toxicities of varying grades. The standard starting dose for RAIR-DTC is $24\\,\\mathrm{mg}$ daily. The specified dose reduction steps are sequentially from $24\\,\\mathrm{mg}$ to $20\\,\\mathrm{mg}$, then to $14\\,\\mathrm{mg}$, and finally to $10\\,\\mathrm{mg}$.\n\n**1. Management of Grade $3$ Hypertension:**\nThe patient developed Grade $3$ hypertension (BP $168/102\\,\\mathrm{mmHg}$). According to prescribing guidelines for lenvatinib:\n- **Action:** For Grade $3$ hypertension, treatment should be **withheld**. The problem states this was done correctly.\n- **Resumption:** Lenvatinib may be resumed once the hypertension is controlled to Grade $\\le 2$ (systolic BP $<160\\,\\mathrm{mmHg}$ and diastolic BP $<100\\,\\mathrm{mmHg}$).\n- **Dose Adjustment:** Upon resumption, the dose should be reduced. As this is the first instance requiring a dose reduction from the starting dose of $24\\,\\mathrm{mg}$, the correct new dose is the first step-down, which is **$20\\,\\mathrm{mg}$ daily**.\n- **Monitoring:** BP should be monitored closely after initiation or dose changes. A standard recommendation is to monitor BP after $1$ week, then every $2$ weeks for the first $2$ months, and monthly thereafter. Monitoring at least weekly for the first couple of months is a clinically prudent and common practice.\n\n**2. Management of Grade $3$ Proteinuria:**\nAfter resuming lenvatinib (presumably at $20\\,\\mathrm{mg}$), the patient developed Grade $3$ proteinuria ($4.2\\,\\mathrm{g}/24\\,\\mathrm{h}$). According to prescribing guidelines:\n- **Action:** For Grade $3$ proteinuria (defined as $\\ge 3.5\\,\\mathrm{g}/24\\,\\mathrm{h}$), treatment should be **withheld**. The problem states this was done correctly.\n- **Resumption:** Lenvatinib may be resumed once proteinuria has improved. The specific guideline states resumption is appropriate when proteinuria is $<2\\,\\mathrm{g}/24\\,\\mathrm{h}$ or $\\le$ Grade $2$. The patient's proteinuria improved to $1.6\\,\\mathrm{g}/24\\,\\mathrm{h}$, meeting this criterion.\n- **Dose Adjustment:** Upon resumption, the dose must be reduced again. Since the current dose level was $20\\,\\mathrm{mg}$, the next dose reduction is to **$14\\,\\mathrm{mg}$ daily**.\n- **Monitoring:** Urine protein should be monitored at baseline and periodically throughout treatment. Typically, a urine dipstick is performed at each clinical visit (e.g., every $4$ weeks). If the dipstick reading is $\\ge 2+$, a quantitative measurement (e.g., a $24$-hour urine protein collection) is warranted to accurately grade the toxicity.\n\n**Consolidated Correct Management Plan:**\n- **For Grade $3$ Hypertension:** Withhold lenvatinib. After BP is controlled to Grade $\\le 2$, resume at a reduced dose of $20\\,\\mathrm{mg}$.\n- **For Subsequent Grade $3$ Proteinuria:** Withhold lenvatinib. After proteinuria improves to $<2\\,\\mathrm{g}/24\\,\\mathrm{h}$, resume at the next reduced dose of $14\\,\\mathrm{mg}$.\n- **Monitoring Schedule:** Monitor BP at least weekly for the first $2$ months, then periodically. Monitor urine protein via dipstick at baseline and every $4$ weeks, with a follow-up $24$-hour collection for results $\\ge 2+$.\n\n**Option-by-Option Analysis**\n\n**A. Withhold lenvatinib for grade $3$ hypertension; resume at $20\\,\\mathrm{mg}$ once BP is controlled to grade $\\le 2$. On subsequent grade $3$ proteinuria ($\\ge 3.5\\,\\mathrm{g}/24\\,\\mathrm{h}$), withhold and resume at $14\\,\\mathrm{mg}$ when proteinuria is $\\le 2.0\\,\\mathrm{g}/24\\,\\mathrm{h}$. Monitor BP at least weekly for the first $2$ months and then periodically; monitor urine protein at baseline and every $4$ weeks, obtaining a $24$-hour urine if dipstick is $\\ge 2+$.**\n- This plan correctly identifies the initial dose reduction to $20\\,\\mathrm{mg}$ for the first Grade $3$ toxicity and the subsequent reduction to $14\\,\\mathrm{mg}$ for the second Grade $3$ toxicity. It specifies the correct actions (withholding therapy) and appropriate resumption criteria. The monitoring schedule is clinically sound and consistent with evidence-based guidelines.\n- **Verdict: Correct**\n\n**B. Continue lenvatinib at $24\\,\\mathrm{mg}$ during grade $3$ hypertension while adding antihypertensives; monitor BP monthly. For grade $3$ proteinuria, continue lenvatinib at $24\\,\\mathrm{mg}$ and monitor urine protein every $3$ months.**\n- This plan violates fundamental safety principles. Lenvatinib must be withheld for Grade $3$ toxicities, not continued. Dose reduction is mandatory upon resumption. The proposed monitoring intervals are dangerously infrequent for active, high-grade toxicities.\n- **Verdict: Incorrect**\n\n**C. For grade $3$ hypertension, reduce lenvatinib directly to $18\\,\\mathrm{mg}$ without interruption; for grade $3$ proteinuria, reduce further to $10\\,\\mathrm{mg}$. Monitor BP daily in clinic for $2$ weeks and urine protein weekly thereafter.**\n- This plan is incorrect on multiple counts. The drug must be interrupted for Grade $3$ toxicity. The dose of $18\\,\\mathrm{mg}$ is not a standard dose level for lenvatinib. The subsequent reduction to $10\\,\\mathrm{mg}$ skips the $14\\,\\mathrm{mg}$ level. The monitoring plan is not standard practice.\n- **Verdict: Incorrect**\n\n**D. Permanently discontinue lenvatinib for any grade $3$ toxicity; instruct the patient to measure BP three times daily at home and check urine protein only if edema develops.**\n- Permanent discontinuation is not recommended for a first occurrence of manageable Grade $3$ toxicities like hypertension or proteinuria. This approach would prematurely deprive the patient of an effective therapy. The monitoring advice for proteinuria is flawed, as significant proteinuria can occur without edema.\n- **Verdict: Incorrect**\n\n**E. Withhold lenvatinib for grade $3$ hypertension; resume at $14\\,\\mathrm{mg}$ when BP is grade $\\le 2$. For grade $3$ proteinuria, withhold and resume at $20\\,\\mathrm{mg}$. Monitor BP twice weekly for $4$ weeks and urine protein every $2$ months.**\n- The dose management here is illogical. The first dose reduction incorrectly skips the $20\\,\\mathrm{mg}$ level and goes directly to $14\\,\\mathrm{mg}$. For the second toxicity, it illogically suggests *increasing* the dose back to $20\\,\\mathrm{mg}$, which is contrary to all principles of toxicity management.\n- **Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4790919"}]}